Pharmacokinetics of the CYP 3A Substrate Simvastatin following Administration of Delayed Versus Immediate Release Oral Dosage Forms

@article{TubiGrozdanis2007PharmacokineticsOT,
  title={Pharmacokinetics of the CYP 3A Substrate Simvastatin following Administration of Delayed Versus Immediate Release Oral Dosage Forms},
  author={Marija Tubi{\'c}-Grozdanis and John M. Hilfinger and Gordon L Amidon and Jae Seung Kim and Paul Kijek and Petra Staubach and Peter Langguth},
  journal={Pharmaceutical Research},
  year={2007},
  volume={25},
  pages={1591-1600}
}
The study was designed to evaluate the effect of delayed release (DR) on absorption and bioavailability of intestinally metabolized drugs after oral dosing, using the HMG-CoA reductase inhibitor simvastatin, a CYP3A substrate, as a model drug. To target drug release and to assess regional gastrointestinal absorption of the CYP 3A substrate simvastatin from the distal parts of the intestine, delayed release film coated tableted oral dosage forms were developed. Simvastatin delayed release tablet… CONTINUE READING

8 Figures & Tables

Connections & Topics

Mentioned Connections BETA
Simvastatin bioavailability was increased by a factor of three , as compared to the reference formulation Zocor®. The overall metabolite levels from the immediate release capsules tended to be higher throughout the period studied than the metabolite levels following administration of Zocor® and simvastatin delayed release dosage form .
Simvastatin bioavailability was increased by a factor of three , as compared to the reference formulation Zocor®. The overall metabolite levels from the immediate release capsules tended to be higher throughout the period studied than the metabolite levels following administration of Zocor® and simvastatin delayed release dosage form .
Simvastatin bioavailability was increased by a factor of three , as compared to the reference formulation Zocor®. The overall metabolite levels from the immediate release capsules tended to be higher throughout the period studied than the metabolite levels following administration of Zocor® and simvastatin delayed release dosage form .
To target drug release and to assess regional gastrointestinal absorption of the CYP 3A substrate simvastatin from the distal parts of the intestine , delayed release film coated tableted oral dosage forms were developed .
To target drug release and to assess regional gastrointestinal absorption of the CYP 3A substrate simvastatin from the distal parts of the intestine , delayed release film coated tableted oral dosage forms were developed .
The study was designed to evaluate the effect of delayed release ( DR ) on absorption and bioavailability of intestinally metabolized drugs after oral dosing , using the HMG - CoA reductase inhibitor simvastatin , a CYP3A substrate , as a model drug .
The study was designed to evaluate the effect of delayed release ( DR ) on absorption and bioavailability of intestinally metabolized drugs after oral dosing , using the HMG - CoA reductase inhibitor simvastatin , a CYP3A substrate , as a model drug .
To target drug release and to assess regional gastrointestinal absorption of the CYP 3A substrate simvastatin from the distal parts of the intestine , delayed release film coated tableted oral dosage forms were developed .
To target drug release and to assess regional gastrointestinal absorption of the CYP 3A substrate simvastatin from the distal parts of the intestine , delayed release film coated tableted oral dosage forms were developed .
The study was designed to evaluate the effect of delayed release ( DR ) on absorption and bioavailability of intestinally metabolized drugs after oral dosing , using the HMG - CoA reductase inhibitor simvastatin , a CYP3A substrate , as a model drug .
The study was designed to evaluate the effect of delayed release ( DR ) on absorption and bioavailability of intestinally metabolized drugs after oral dosing , using the HMG - CoA reductase inhibitor simvastatin , a CYP3A substrate , as a model drug .
All Topics